Type I interferon is important in anti-viral responses and in coordinating the innate immune response. Here we explore the use of interferon-β to adjuvant the response to a rabies virus (RV) vaccine vector expressing both HIV-1 Gag and IFN-β. Viral load and immune responses of immunized mice were analyzed over time.
Introduction
Traditional vaccine approaches, such as live-attenuated viruses, have been very successful in providing immunity to some of mankind's largest microbial threats. One such success story was the use of an attenuated vaccinia virus to immunize people against smallpox infection (Parrino and Graham, 2006) . However, similar approaches cannot be used or have failed to control other infectious diseases, such as HIV-1. Thus, vaccine development requires novel approaches and potentially the use of a molecular adjuvant to increase immune response (Letvin, 2006) .
Live attenuated vaccine vectors have the greatest potential for generating broad-scope immunity and their usefulness has been shown in different settings. We have generated a vaccine vector based on attenuated Rabies virus (RV) expressing HIV-1 or SIV antigens that has proven to be highly immunogenic in mice and has protected nonhuman primates from a AIDS-like disease (McGettigan et al., 2001; McKenna et al., 2007) .
RV is an enveloped non-segmented negative strand RNA virus of the Rhabdoviridae family. Although wild type RV almost always causes a fatal CNS disease in mammalian species , in its attenuated form, RV has proved to be an excellent vaccine vector (Faber et al., 2005; McGettigan et al., 2003b; McKenna et al., 2007; Siler et al., 2002) . Furthermore, attenuated RV has been shown to induce both a strong cellular and humoral immune response to foreign genes (McGettigan et al., 2003a; McKenna et al., 2007 McKenna et al., , 2003 . RV has a relatively simple genome organization encoding five structural proteins: a nucleoprotein (N), a phosphoprotein (P), a matrix protein (M), a glycoprotein (G), and an RNA-dependent RNA polymerase (L). RV-N encapsidates the viral RNA and together with RV-P and polymerase L composes the ribonucleoprotein (RNP) complex. RV-M bridges the RNP complex with the transmembrane domain of RV-G (Mebatsion et al., 1999) . Both RV-M and RV-G facilitate virion budding from an infected cell (Mebatsion et al., 1996 (Mebatsion et al., , 1999 .
The RV lifecycle is thought to be sensitive to several anti-viral proteins that are induced by type I interferon (IFN) and thus, RV has developed at least two mechanisms by which it can antagonize type I IFN induction and signaling. In addition to serving as the non-catalytic cofactor to polymerase L, RV-P also inhibits the phosphorylation of IRF-3 at serine-386 by interfering with TBK-1 (Brzozka et al., 2005) . Furthermore, the C-terminal domain of RV-P can bind to the coil-coil domain of Stat1 and efficiently prevent the nuclear accumulation of Stat1 (Brzozka et al., 2006; Vidy et al., 2005 Vidy et al., , 2007 . Thus, RV-P interferes with both the induction and signaling of type I interferon.
Type I interferon, although originally recognized for its anti-viral properties, has recently gained recognition for its role in coordinating the innate and adaptive immune responses. Type I IFN expression may bias immune responses toward Th1 responses (Wenner et al., 1996) , and, in addition, IFN-α/β plays an important role in the clonal expansion of antigen-specific CD8+ T cells. Adoptive transfer of interferon receptor knockout (IFNAR−/−) CD8+ T cells into wild type hosts highlighted the necessity of IFN-α/β signaling in T cells to induce Virology 382 (2008) [226] [227] [228] [229] [230] [231] [232] [233] [234] [235] [236] [237] [238] survival of LCMV-specific CD8+ T cells during the proliferative phase (Kolumam et al., 2005) .
Type I IFN not only affects T cell responses, but, has also been shown to augment the immune response by activating antigen presenting cells (APC). Dendritic cell (DC) maturation following infection with LCMV (Montoya et al., 2005) and Herpes simplex virus type-1 (Pollara et al., 2004) has been shown to be type I IFN dependent. Additionally, subsequent to transfection with two recombinant adenovirus (Ad) vectors, it was seen that DCs upregulated the expression of phenotypic activation markers. The increase was independent of viral replication and toll like receptor (TLR) signaling. However, there was only a marginal increase of costimulatory molecules on the surface of BM-DC derived from IFNAR −/− mice, suggesting that the maturation of Ad-transduced cells was dependent on type I IFN signaling (Hensley et al., 2005) . Furthermore, following maturation in the presence of type I interferon and GM-CSF, monocyte-derived DCs more effectively stimulate an antigen-specific CD8+ T cell response than DCs matured with GM-CSF and IL-4 (Santodonato et al., 2003) .
It is apparent that IFN-α/β plays an important role in directing the adaptive immune response. This function also suggests that it may be a valuable adjuvant in vaccine development. However, much of the work supporting the immune-modifying functions of IFN-β have been done in vitro; therefore, the potential use of IFN as an adjuvant in vaccine development needs to be further investigated. In an attempt to induce IFN-α/β expression in a vaccine for respiratory syncytial virus (RSV), Martinez-Sobrido et al. inserted the RSV-F protein into a Newcastle disease virus (NDV) vaccine vector. Although the recombinant virus increased IFN-α/β levels, as predicted, and protected mice against RSV challenge the mechanism of protection was unclear, because similar protection was seen in IFNAR−/− and wild type mice (Martinez-Sobrido et al., 2006) . When combining multiple viral proteins, it may be impossible to distinguish the direct effects of the interferon from the immunological response to the additional protein. Furthermore, different viruses have several distinct features in addition to their ability to induce IFN, which make results difficult to analyze. Here we use a system in which IFN-β is expressed by the RV vaccine vector in order to compare the immune responses induced in the presence or absence of increased levels of IFN-β.
The use of IFN-β to promote the induction of a stronger CD8+ T cell response might be beneficial for certain vaccine approaches. Although little evidence is available to link the beneficial outcome of a RV infection to increased CTL responses against RV as a vaccine vector, increased CTL responses to the foreign antigen may be required. In order to further investigate the potential immuneenhancing effects of IFN-β, we constructed two recombinant Rabies viruses, one expressing both HIV-1 Gag and IFN-β and the other expressing HIV-1 Gag and IFN-β minus the ATG start codon. Our data support the hypothesis that IFN-β works at the interface of the innate and adaptive immune response by sustaining the pool of activated antigen-specific CD8+ lymphocytes. Thus, in addition to controlling viral replication (a well-studied effect of type I IFN), we provide evidence that IFN-β also directs the cells of the adaptive immune system to adequately respond to a pathogen. Elucidating the immune-modifying effects of type I IFN is important in determining whether the addition of this cytokine can enhance the cellular response and increase the potency of RV-based vaccine vectors.
Results

Construction and characterization of the recombinant RV
To investigate the effect of type I interferon on the adaptive immune response, we used a previously well-characterized RV vaccine vector encoding HIV-1 Gag (Fig. 1A , denoted BNSP-Gag) (McGettigan et al., 2001 ). For our purposes, the gene encoding mouse IFN-β was introduced between the RV-G and L genes resulting in virus that expressed both HIV-1 Gag and IFN-β (Fig. 1A , denoted IFN (+)). Of note, it is well established that the expression of an additional gene can change the growth characteristics of RV (McGettigan et al., 2006) . Thus, in order to have the proper control, we also cloned the mouse IFN-β gene without the ATG start codon between the RV-G and L genes (Fig. 1A, denoted IFN(−) ). Recombinant viruses were recovered by standard methods as previously described (Tan et al., 2007) .
We then evaluated the expression of IFN-β by the two recombinant RVs IFN(+) and IFN(−). Production of IFN-β was quantified in viral supernatant via ELISA 48 h post infection (Fig.  1B) . We detected only background levels of IFN-β in the supernatants of BSR cells infected with IFN(−), presumably due to the IFN antagonistic activity of RV-P (Brzozka et al., 2005; Brzozka, Finke, and Conzelmann, 2006; Vidy et al., 2005 Vidy et al., , 2007 . On the other hand, BSR cells infected with the IFN(+) virus produced approximately 3.5 μg/ml IFN-β, which is a 1000-fold increase over background. Next, we aimed to assess the biological functionality of the IFN-β expressed by the recombinant RV. Briefly, we infected BSR cells with IFN(+), IFN(−) or BNSP for 48 h. The supernatant from each sample was then collected and UV-inactivated. Serial dilutions of the supernatants were then used to pre-treat mouse NA cells for 24 h prior to infecting the NA cells with recombinant VSV expressing GFP (Stojdl et al., 2003) . Five hours after infection with VSV-GFP, NA cells were analyzed for expression of GFP, a marker for VSV replication in our system. Type I IFN is known to efficiently inhibit VSV replication in neurons (Trottier et al., 2005) ; thus, if functional IFN-β is present in the supernatant, we should not see GFP expression. As shown in Fig. 1C , only supernatants from IFN(+) infected cells efficiently inhibited VSV replication, indicating the presence of functional IFN-β in that sample.
The expression of HIV-1 p55 was determined by immunostaining infected BSR cells. Recombinant RV BNSP IFN(−) and IFN(+) were analyzed with antibodies directed against RV-N or HIV-1 p24.
The results indicate that all viruses infect the cells (Fig. 1D , anti-RV-N) and both IFN(−) and IFN(+) RV express HIV-1 Gag (Fig. 1D , anti-HIV-1 p24).
Characterization of recombinant viruses growth kinetics
To determine whether the expression of both IFN-β and HIV-1 Gag in the RV genome altered the growth kinetics of RV we analyzed viral growth by multi-step and one-step growth curves. It is well documented that IFN-β is a potent anti-viral; therefore, we analyzed growth kinetics on both type I IFN responsive and nonresponsive cells. It was determined that both NA and BSR cells can produce type I IFN following Sendai virus infection. Of the two, however, only NA cells are responsive to mouse IFN-β and, thus, able to inhibit VSV replication (data not shown). Cells were infected with an MOI of 0.1 (multi-step) or 10 (one-step). Aliquots of the supernatants were collected at various time points, and the titers were determined. The multi-step and one-step growth curves derived from infected BSR cells illustrated that IFN(+) and IFN(−) viruses grew with similar kinetics and to relatively equal titers (Figs. 2A, C) , indicating that the expression of IFN-β did not affect viral growth by a type I IFN independent mechanism. Of note, the titer for both IFN(+) and IFN(−) viruses was about 10-fold less than the titer of the parent virus strain, BNSP-Gag, at all time points presumably due to the insertion of the IFN-β gene between RV-G and RV-L. However, when IFN-β sensitive cells were used, there was a significant difference in the growth kinetics of IFN(+) and IFN(−) RV. For both one-step and multi-step growth curves there is a delay in viral growth and approximately a 2.5 to 3 log decrease in the final titer of the IFN(+) virus (Figs. 2B, D) . Thus, IFN-β expressed by RV exhibits anti-viral properties when grown on IFN sensitive cells.
Immunogenicity of recombinant RV in Balb/c mice following mucosal immunization
In order to characterize how the increased expression of IFN-β following a RV infection would impact the immunogenicity and pathogenicity of RV vaccine vectors, BALB/c mice were immunized intranasally with 1.5 × 10 5 ffu of IFN(+) or IFN(−). We infected the mice intranasally in order to see the effect on pathogenicity, because it has been shown that the first generation vaccine vector, BNSP-Gag, is apathogenic after peripheral inoculation while still lethal after intranasal or intracranial inoculation (McGettigan et al., 2003b) . We saw that the survival of mice infected with the IFN(+) virus was significantly greater than the survival of those mice infected with the recombinant RV which did not express IFN-β (Fig. 3A) . As expected, this suggested that expression of IFN-β results in increased survival of IFN(+) immunized mice. We next sought to determine whether the increased survival was due to the anti-viral activity or immune-modifying activity of IFN-β. Again, mice were immunized intranasally with IFN(+) and IFN(−), and then the brains and the spleens of infected animals were taken at various times post infection. Viral RNA in the brain was quantified using qPCR specific for RV-N as previously described (Tan et al., 2007) . As shown in Fig. 3B , there was an average 1000-fold decrease in viral messenger RNA on day 8 and a 100-fold decrease in mRNA on day 12 when mice were infected with the IFN(+) virus as compared to mice infected with the control IFN(−) virus. Of note, the viral genomic RNA on day 8, 12, and 15 was about 10-fold lower than the messenger RNA for each mouse (data not shown). Thus, in vivo IFN-β expression had a similar attenuating effect on viral growth as was seen in tissue culture and efficiently decreased the viral load during the first 12 days of infection. The splenocytes of the mice from above were analyzed to evaluate the immune-modifying effect of IFN-β on the RV vaccine vectors. Due to the low precursor frequency of antigen-specific cells in a wild type mouse, we looked at the percentage of activated cells (CD44 hi CD62L lo ) in the CD8+ lymphocyte population. This shows the immune response to the entire vaccine vector and not just to the HIV-1 gag protein. Surprisingly, we saw that, despite a large decrease in viral load in IFN(+) infected animals at 8 dpi, there were similar numbers of activated CD8+ T cells recovered from IFN(+) and IFN(−) infected animals. Furthermore, at 12 dpi, there was a significant increase in the percentage of activated CD8+ splenocytes in the IFN(+) infected animals despite the 100-fold decrease in viral antigen (Figs. 3C, D). Thus, although mice infected with the IFN(+) virus probably had a lower amount of viral antigen at 8 and 12 dpi due to the anti-viral effects of IFN-β, these mice had similar (day 8) or significantly greater (day 12) CD8+ T cell responses. In order to determine whether this effect is specific to the route of immunization we also looked for T cell activation in the inguinal lymph nodes and spleens of mice immunized intramuscularly. Consistent with what was seen after intranasal immunization, 8 dpi there was no significant difference between the activated T cells found in the IFN(+) and IFN(−) immunized mice (data not shown). Thus we conclude that during the primary immune response, IFN-β is acting as an adjuvant for the cellular immunity. Type I IFN has also been shown to affect antibody development following influenza infection (Heer et al., 2007) . To determine the impact that IFN-β expression has on the humoral immune response in our vaccine strategy, mice were bled at various times post infection, and sera was analyzed for RV-G antibodies. It was seen that total IgG levels increased when the mice began to lose weight (Figs. 4A-D) , and IFN(−) immunized mice had appreciable RV-G IgG levels in their sera at earlier timepoints than IFN(+) immunized mice. Moreover, three out of seven IFN(+) mice never developed RV-induced pathology but also never produced anti-RV antibodies, indicating that the innate immune response via IFN-β can clear RV infection. We concluded from this experiment that humoral responses are determined in large part by viral replication.
To determine whether the delayed kinetics of antibody production in mice vaccinated with IFN(+) was due to a persistent infection of IFN (+) RV, we quantified the viral messenger RNA at day 15 (when mice first exhibited signs of disease) and at 19 dpi (when mice were at their lowest body weight). We saw that at day 19 the level of viral RNA message was decreasing and most of the mice have around 10 2 copies of viral mRNA/μg RNA (Fig. 4E ). Of note, the one mouse that had a high level of viral messenger RNA 19 dpi had the lowest amount of virus at 15 dpi, thus it is possible that the kinetics of viral replication in that mouse was highly delayed. Therefore, it seems unlikely that the IFN(+) virus is persisting long term in the mice, but rather the kinetics of viral replication may be delayed by the addition of IFN-β.
Immunogenicity of recombinant RV in IFNAR−/− mice following mucosal immunization
In order to establish that the differences seen in BALB/c mice were dependent on the expression of IFN-β, we repeated the evaluation of viral load and immunogenicity in interferon receptor knockout (IFNAR −/−) mice. Type I IFN signals through a heterodimeric receptor to initiate the JAK/ STAT signaling pathway (Randall and Goodbourn, 2008) . One of the receptor subunits is knocked out in the IFNAR−/− mice rendering them unable to initiate the IFN-β signaling cascade (Muller et al., 1994) . Following immunization, the IFNAR−/− mice receiving either the IFN(+)or the IFN(−) immunization did not show significant differences in survival (Fig. 5A) . Likewise, 8 dpi there was no significant difference in the amount of viral messenger RNA isolated from the brains of mice that had been immunized with IFN(+) or IFN(−) vaccine vectors (Fig. 5B ). In addition, the percentage of CD44 hi CD62L lo cells in the CD8+ population was equal in mice immunized with IFN(+) or IFN(−) (Figs. 5C, D) . Taken together, these data suggest that the differences we observed in wild type BALB/c mice immunized with IFN (+) and IFN(−) viruses were due to IFN-α/β signaling.
Increased levels of type I IFN do not increase the activation level of antigen presenting cells, but may promote increased survival of CD8+ T cells following antigen encounter
In order to more fully understand the role of IFN-β in the primary immune response following viral infection, we sought to determine (Fig. 6A) . However, there was no significant difference in the fold increase over uninfected cells in CD80 expression when comparing IFN(+) and IFN(−) infected cells at any time point. Similarly, we saw that following infection of JAWSII cells with either IFN(+) or IFN(−) RV equally induced the upregulation of CD86 expression (Fig. 6B) . In order to more clearly distinguish the effect of IFN-β from the RV infection a supplementary experiment was performed in which the supernatant from IFN(+) or IFN(−) infected JAWSII cells was used to activate uninfected JAWSII cells. After 24 or 48 h, there was no significant difference in the activation state, as determined by expression of CD80 and CD86, of JAWSII cells treated with UV-inactivated supernatant from IFN(+) or IFN(−) infected cells compared to cells treated with uninfected supernatant. Thus, it seems that incorporating IFN-β into the RV construct does not significantly increase DC activation. Therefore, it seems unlikely that the difference we observed in CD8+ T cell activation was a result of increased costimulation by APCs. IFN-β does not appear to increase maturation of APCs; therefore, we next investigated the impact that IFN-β has on the antigen-specific CD8+ T cell population in our vaccine strategy. To determine the direct effect of IFN-β on T cells, we developed a transfer model in which all of the T cells in the mouse were either wild type (responsive to IFN) or IFNAR−/− (non-responsive to IFN). Briefly, we isolated CD3+ T cells from BALB/c or IFNAR−/− mice and then transferred 3 × 10 6 cells intraperitoneally into Nude mice (Fig. 7A) . Nude mice have a very small number of mature α/β-T cells with limited functionality in the periphery (Kindred, 1979; Kishihara et al., 1987; Yoshikai et al., 1986) . In this transfer model, the only T cells able to respond to infection are those we transferred to the mice one day prior to infection with the IFN(+) virus. In analyzing the splenocytes, we saw no difference in the percentage of activated CD8+ T cells in the spleens of BALB/c or IFNAR−/− recipient mice 12 dpi (Fig. 7B) . However, we did notice that the total number of CD8+ cells recovered from the BALB/c recipient mice tended to be greater than the number recovered from the IFNAR −/− mice (Fig. 7C ). This trend approached significance when comparing CD8+ T cell number (p = 0.0661), however was not significant when comparing CD4+ T cell number (p = 0.3326). We conclude that IFN-β signaling may be important to sustain the population of antigenspecific T cells following infection.
Recall response to HIV-1 Gag
The proof of principle in all vaccine studies is a challenge model. To assess the effect of IFN-β on the development of long-term memory cells, a key requirement for any vaccine, we intramuscularly (i. Immunized BALB/c mice were rested for at least 60 days and then challenged intraperitoneally (i.p) with 10 6 plaque forming units (pfu) of vaccinia virus expressing HIV-1 Gag (vv-Gag). The HIV-1 Gag specific recall response was analyzed 5 days later by evaluating expression of Gag specific T cell receptors (TCR) with an AMQMLKETI-H2K d specific tetramer. Additionally, the functionality of the memory cells was determined by intracellular cytokine staining. There was no significant difference in the number of tetramer positive CD8+ T cells present following immunization with IFN(+) or IFN(−) RV (Fig. 8A) . However, the IFN(+) immunized mice seemed to fall into 2 groups: high responders and low responders (percentage of tetramer+ CD8+ cells less than 10%). When considering the functionality the CD8+ T cells, we saw no difference in the induction of cytokines between IFN(+) and IFN(−) immunized animals (Fig. 8B) . The expression of IFN-γ and IL-4 was induced at the highest level, while very little IL-2 an IL-10 was induced. Taken together, these results indicate that although IFN-β enhances the primary immune response (Fig. 3) , the adjuvant effect of IFN-β in a viral vaccine vector only induces minimal long-term benefits as reflected by the long-term memory response.
Discussion
Here we have analyzed the effect of IFN-β on viral replication, primary CD8+ T cell activation, and memory T cell development in order to assess its use as a molecular adjuvant in vaccine development. We see that IFN-β expression efficiently decreases the viral titer and reduces vector pathogenicity (Figs. 2 and 3A) . Therefore, IFN-β could be added to RV-based vaccine vectors to reduce vector-associated pathogenicity and to increase safety. Furthermore, the anti-viral activity of IFN-β could potentially lead to a self-limiting infection, making it more appealing for use in immuno-compromised individuals. Increased expression of type I IFN during priming has a significant effect on the cellular immune response. Despite having significantly less viral antigen, there was a significantly greater percentage of activated CD8+ T cells in the spleen at 12 dpi (Fig. 3) . This highlights the potential strength for using IFN-β as an adjuvant in vaccine development. Although there is a significant effect on the primary immune response, the memory immune response seems to be unaffected by the addition of IFN-β into the RV vaccine vector (Fig.  8) . We hypothesize that the anti-viral activity of IFN-β during priming counterbalanced the immune-enhancing capability of IFN-β and thus no significant increase on memory cell formation was achieved.
The RV vaccine vector has already been shown to be safe (McGettigan et al., 2003b; McKenna et al., 2007) , but here we show that the addition of IFN-β into the genome can work to further attenuate the virus. The recombinant IFN(+) and IFN(−) viruses were attenuated compared to the parental BNSP-Gag as seen by the 10-fold reduction in titer at all time points in the growth curve (Fig. 2) . Viral replication was significantly decreased in an IFN-β dependent manner, reaffirming the anti-viral effects of type I IFN on negativesense RNA viruses (Randall and Goodbourn, 2008) . Both the addition of a second gene into the RV genome and the anti-viral activity of IFN-β attenuated the RV vaccine vector. This attenuation was seen in vivo as an increased survival of IFN(+) immunized mice (Fig. 3A) .
In addition to attenuating the virus, we saw that IFN-β was able to significantly increase the cellular immune response following immunization. Surprisingly, we saw that at 12 dpi CD8+ T cell activation was significantly greater following infection with the IFN(+) virus, despite the noted 100-fold decrease in viral load. Furthermore, with 1000-fold less virus in the brain at 8 dpi, there was still an equal activated CD8+ T cell response. Both of these facts indicate that IFN-β is a potent adjuvant for cellular immunity. Furthermore, the studies in IFNAR−/− mice indicate that the differences seen here are type I IFN dependent. This data supports the use of IFN-β to enhance the immune response to vaccine vectors that are given even at a low MOI. In order to further understand the adjuvant properties of IFN-β we sought to determine the mechanism by which IFN-β was increasing the primary CD8+ T cell response following immunization with the IFN(+) virus. In our hands, APC activation does not seem to be affected by increased levels of IFN-β. Infection with RV however is not the only viral infection that induces APC maturation in a type I IFN independent manner. Similarly, DC maturation following Sendai virus infection has been shown to work independently of the IFN pathway (Lopez et al., 2003) . Although a strong correlation between DC maturation and type I IFN induction was observed, it was determined using anti-IFN antibodies that the secreted IFN was neither necessary, nor sufficient to induce full DC maturation (Lopez et al., 2003) . Furthermore, it was seen that, following adenovirus infection, type I IFN was necessary for DC to undergo full maturation. However, both wildtype and IFNAR−/− mice could mount a strong antigen-specific CD8+ T cell response (Hensley et al., 2005) . Therefore, it is not surprising that the differences we saw in CD8+ T cell activation in the presence or absence of exogenous IFN-β were not functions of DC and macrophage activation.
Instead, the immune-enhancing activity of IFN-β in our vaccine strategy seems to directly impact CD8+ T cells. Although our transfer experiment does not definitively prove that IFN-β is needed to sustain a population of antigen-specific CD8+ T cells, the experiment supports this conclusion. Therefore, it is likely that IFN-β signaling through a receptor on a CD8+ T cell is required either as a signal to promote differentiation of effector cells or as a signal to resist activation-induced cell death. It was seen that IFN-α or IL-12 treatment was required during naïve CD8+ cell priming to induce proliferation and cytolytic activity. Beads coated with MHC I-peptide and CD80 co-stimulatory ligand are unable to sufficiently prime naïve CD8+ T cells. However, T cells stimulated by the same beads in the presence of IFN-α/β are capable of cytolytic function and IFN-γ production (Curtsinger et al., 2005) . On the other hand, IFN-α/β can also prevent activation-induced cell death of T cells following nonspecific activation with staphylococcal enterotoxin B (Marrack et al., 1999) . Our model does not allow us to distinguish between these two possibilities; however, it is in support of a direct role for IFN-β during priming. This piece of evidence is important and should be considered during vaccine development.
Despite the undeniable adjuvant effect induced by IFN-β that we saw during the primary immune response, we did not see a significant increase in antigen-specific cells following vv-Gag challenge months later. However, there was much less antigen at the site of viral replication (the brain) in these mice. It has been suggested that there exists a diverse repertoire of T cells to a single epitope and that antigen load can influence in vitro recall responses (Naumov et al., 2006) . Furthermore, the antigen dose can influence the quality of the CD8+ T cell that is induced following infection. In a study done by Alexander-Miller it was seen that higher avidity cells were induced at lower peptide concentrations. However, it was also observed that lower avidity T cells preferentially survived into memory cells (Alexander-Miller, 2000) . Therefore, since memory cell differentiation is also impacted by the amount of antigen, the immune-enhancing effects of IFN-β may be counterbalanced by low antigenic loads, thus yielding a minimal change to the overall memory cell development. Thus, IFN-β may be a better adjuvant choice in a DNA or subunit vaccine where the vaccine vector is not deleteriously impacted by the cytokine.
Another consideration to be made is that type I IFN has been reported to have different effects on T cells in various activation states. The result of IFN-α/β signaling in an activated T cells is different then the response in a naïve T cell. Naïve human CD4+ T cells that were pre-treated with IFN-α had a delayed entry into the cell cycle. On the other hand, the presence of IFN-α following nonspecific stimulation of human CD4+ T cells with anti-CD3/ anti-CD28 antibodies did not inhibit T cell proliferation (Dondi et al., 2003) . This study did not however consider how type I IFN affects CD8+ T cells or memory precursor T cells. Thus, despite the positive impact that IFN-β had on effector cells during priming, little can be concluded as to whether or not IFN-β had the same effect on memory precursor cells.
Materials and methods
Plasmid construction
The gene encoding mouse IFN-β, pORF-mIFNB (Invitrogen), was used as a template and was amplified by PCR using Vent polymerase (New England Biolabs Inc.) and the primers 5′-TTTCGTACGATCATGAACAACAGGTGGATCCTC-3′ and 5′-AAAGC-TAGCTC AGTTTTGGAAGTTTCTGGTAAG-3′ containing the BsiWI or NheI restriction sites (underlined). The resulting PCR fragment was gel purified and digested with BsiWI and NheI. The digestion products were ligated into a plasmid encoding recombinant RV vaccine vector, pSPBN (McGettigan et al., 2003b) , which had been previously digested with BsiWI and NheI. The resulting plasmid was designated pSPBN-IFN(+). Alternatively, mouse IFN-β was amplified by PCR using the primers 5′-TTTCGTACGATCAACAA-CAGGTGGATCC TCCAC-3′ and 5′-AAAGCTAGCTCAGTTTTG-GAAGTTT CTGGTAAG-3′ containing the BsiWI or NheI restriction sites (underlined) and lacking the ATG start codon. The PCR fragment was gel purified, BsiWI and NheI digested, and ligated into the BsiWI/NheI-digested pSPBN. The resulting plasmid was designated pSPBN-IFN(−). The plasmid encoding a recombinant RV vaccine vector expressing HIV-1 Gag (pBNSP-Gag) has been described previously (McGettigan et al., 2001) . The pSPBN-IFN(+) and pSPBN-IFN(−) plasmids were digested with Pml I and Nco I. The digestion fragment containing either the IFN(+) or IFN(−) gene was ligated into pBNSP-Gag previously digested with Pml I and Nco I. The generated plasmids were designated IFN(+) and IFN(−), respectively. The introduced sequence for each plasmid was confirmed by sequencing.
Recovery of recombinant viruses
Recombinant RV virions were recovered by a system described previously (Tan et al., 2007) . Briefly, FuGENE 6 Transfection Reagent (Roche Diagnostics) was used to co-transfect 6 plasmids into BSR cells (a BHK-21 cell clone) in 6-well plates. The concentrations of plasmids (per plate) were as follows: 2.5 μg recombinant RV cDNA, 1.25 μg RV-N, 0.75 μg T7 polymerase, 0.63 μg RV-P and RV-L, and 0.5 μg RV-G. The plasmids encoding the recombinant RV cDNA and RV-N, P, G, and L were under the control of the T7 promoter (Finke et al., 2003) ; the plasmid encoding the T7 polymerase was under the control of the chicken actin promoter with an enhancer from the CMV immediate early gene. 3-7 days after transfection the supernatant was collected from each well and BSR cells were stained with a fluorescein isothiocyanate (FITC)-conjugated anti-RV-N antibody (Centacor, Inc.) to identify wells with infectious virus. Supernatant from RV-positive wells was used to infect a T25 flask of BSR cells and increase the viral yield. One-step and multi-step growth curves BSR and NA cells were infected with BNSP-Gag, IFN(+) or IFN(−) in serum-free media at a MOI of 10 (for the one-step growth curve) or of 0.01 (for the multi-step growth curve). Following 90 min incubation at 37°C, the virus was aspirated, and cells were washed twice with PBS to remove any virus that had not yet infected the cells. Serum-containing media was then added to the cells, and, at indicated time points, 0.3 ml of supernatant was removed and stored at 4°C. The aliquots were titered in duplicate on BSR cells. Mice in the recall response experiments were rested at least 60 days after intramuscular immunization with IFN(+) or IFN(−) and then were challenged intraperitoneally (I.P.) with 10 6 pfu of recombinant vaccinia-expressing HIV-1 Gag. Mice were euthanized 5 days after challenge, and their spleens were harvested for further analysis. For the transfer experiments CD3+ cells were isolated from the spleens of BALB/c or IFNAR−/− mice by a Dynal T cell negative isolation kit (Invitrogen) according to the manufacturers protocol. The purity of CD3+ cells was assessed by flow cytometry and determined to be N90%. 3 × 10 6 CD3+ cells were transferred into Nude mice I.P. One day after transfer, mice were infected with 10 6 ffu IFN(+) intramuscularly. Mice were euthanized 12 days after immunization, and their spleens were harvested for further analysis.
IFN-β and RV-G enzyme-linked immunosorbent assays (ELISA)
For the IFN-β ELISA, BSR cells were infected with IFN(+) or IFN(−) at an MOI of 0.5 or left uninfected for 48 h. Supernatant was collected and spun at 1,600 rpm to remove any cellular debris. Viral supernatant was diluted 1:1000, 1:2000, 1:4000, 1:8000, or 1:16,000 and the amount of IFN-β in each sample was quantified using a mouse IFN-β ELISA kit (PBL Biomedical Laboratories) according to the manufacturer's protocol. RV-G ELISA was done as described previously (McGettigan et al., 2001) . Briefly, Maxisorb plates (Nunc) were coated with 200 ng/ml purified RV-G protein diluted in Na 2 CO 3 at 4°C O/N. Plates were washed with 0.1%Tween PBS and blocked with 5% milk/PBS for 30 min at RT. Serum collected from RV-infected mice at various time points post infection was diluted in PBS and added to the plate in duplicate. Following a 1 h incubation at RT, the plate was washed with 0.1% Tween PBS. Goat anti-mouse IgG conjugated-HRP (Southern Biotech) was added at a final concentration of 200 ng/ml, and plates were incubated at 37°C for 30 min. Plates were washed with 0.1% Tween PBS and developed with o-phenylenediamine dihydrochloride fast tablet peroxidase substrate (Sigma) for 20 min. The colorimetric reaction was stopped with 3 M H 2 SO 4 , and the absorbance for each well was determined at 490 nm.
Quantitative real time PCR
Virus load in the brains of infected mice was determined by TaqMan probe-based real time PCR as described previously (Tan et al., 2007) with the following modification: For genomic RNA, samples were standardized with the equation (y = − 3.2211x + 38.394, R 2 = 0.9999), and for RV messenger RNA samples were standardized with the equation (y = − 3.1406x + 36.764, R 2 = 0.9996). The copy number was normalized to 1 μg/μl total RNA.
Flow cytometry
For surface staining of splenocytes, spleens from infected mice were homogenized, and a single-cell suspension was prepared. Erythrocytes were removed with ACK lysing buffer (Sigma Inc), and splenocytes were counted by trypan blue exclusion. Cells were washed in FACS buffer (2% BSA/PBS) and blocked on ice for 1 h with 2 μl rat anti-mouse CD16/CD32 (Fc block) (BD Biosciences Pharmigen) and 3.3 μl unconjugated streptavidin in 100 μl FACS. Cells were washed in FACS buffer and then stained with fluorescent antibodies for 30 min at RT. After staining, cells were washed with FACS buffer and fixed with Cytofix (BD Biosciences) for 16-18 h at 4°C.
For internal staining of splenocytes, samples were stimulated with 10 μg/ml of AMQMLKETI peptide or left unstimulated for 16 h. GolgiBlock (BD Bioscience) was added for 6 h and then cells were stained as above for any surface molecules. Following fixation, cells were washed twice in Perm/Wash Buffer (BD Bioscience). They were then stained for 30 min at room temperature for internal molecules.
For staining of the APC cell lines, at various time points post infection (MOI = 10) cells were collected and blocked on ice for 30 min with 2 μl Fc block (BD Biosciences Pharmigen) in 100 μl FACS. Cells were washed twice in Perm/Wash Buffer (BD Bioscience) and then stained with fluorescent antibodies for 30 min at RT. After staining, cells were washed with FACS buffer and fixed with Cytofix (BD Biosciences) for 16-18 h at 4°C.
Antibodies used include: PE-AMQMLKETI tetramer (Becton Dickinson), FITC-CD44, PerCP-CD8α, APC-CD62L, FITC-CD4, PE-CD80, PE-CD86, FITC-IFN-γ, APC-TNF-α, APC-IL-2, PE-IL-4, PE-IL-6, FITC-IL-10 (BD Biosciences Pharmingen), and RV-N (Centacor, Inc). All samples were analyzed on BD FACS Calibur 100,000-150,000 events were counted for splenocyte samples and 50,000 events were counted for APC cell lines.
